An Open-Label, Single-Dose, Parallel-Group Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine
Phase of Trial: Phase I
Latest Information Update: 18 May 2017
At a glance
- Drugs Esketamine (Primary)
- Indications Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 12 May 2017 Status changed from active, no longer recruiting to completed.
- 24 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 24 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 Mar 2017.